Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib Trial TO Prevent FOP (STOPFOP)
NCT04307953Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of saracatinib in fibrodysplasia ossificans progressiva (FOP), sponsored by Amsterdam University Medical Center. Started Aug 2020; status: active, not recruiting.
02
Drugs
saracatinib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT04307953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04307953.